• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Wejo Appoints John Maxwell as Chief Financial Officer

    3/16/21 10:12:00 AM ET
    $AQST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AQST alert in real time by email

    MANCHESTER, England & DETROIT--(BUSINESS WIRE)--Wejo, the leader in connected vehicle data, today announced that Chief Financial Officer Barry Nightingale is planning to retire and John Maxwell has been appointed his successor in the role. The changes to the leadership team are effective immediately and come at a time of significant growth for the company, which enables mobility intelligence by 12 billion data points a day from 10.6 million vehicles out of a supply base of 50 million vehicles.

    During his tenure at Wejo, Nightingale helped lead the company from early-stage tech startup to global connected vehicle data leader. This included the $42 million of recent funding to ensure the Wejo team could remain at the forefront of the high growth connected vehicle market. Under his financial leadership, Wejo was named “Fastest Growing Company of the Year” at GP Bullhound’s Northern Tech Awards and established robust finance, legal and compliance teams and processes. Nightingale will continue to advise the company through early 2022.

    “Barry has been a savvy financial leader and sage business counselor through some of our most critical moments of growth, and I’m grateful for all he has done to get Wejo to this inflection point,” said Richard Barlow, founder and CEO of Wejo. “He leaves big shoes for John to fill, but I have every confidence the company will remain on strong financial footing in the months and years ahead under his leadership.”

    Maxwell will report directly to Barlow and work closely with the entire executive team and the Board of Directors as the company enters its next phase of growth. He will be responsible for delivering strong financial results through revenue growth and cost management, capital markets transactions, investor relations and board management. Maxwell will be based in the New York City area.

    Maxwell comes to Wejo with more than 30 years of experience driving financial growth in highly successful start-ups in complex industries including tech and telecom. Most recently, he was CFO of Aquestive Therapeutics (Nasdaq: AQST), a specialty pharmaceutical company with a focus on epilepsy and allergy treatments. During his four-year tenure at the company, he prepared AQST for its IPO, raising $115 million of new equity capital in its 2018 IPO and 2019 follow-on. In addition, Maxwell led a $100 million debt recapitalization and a $125 million royalty monetization transaction at Aquestive. Prior, he was SVP of finance and administration at PanAmSat (NYSE: PA), a global satellite telecommunications business, which he helped take private in a transaction lead by KKR in 2003 and subsequently brought public on the NYSE in 2005. He was also CFO at private equity-backed WIL Research, a contract research organization, which was acquired by Charles River Laboratories in 2016. He started his career at Ernst & Young, and held various senior financial roles at General Signal, ADP, INFONXX and Plainfield Asset Management.

    “Having worked at a variety of high-growth companies where I was responsible for taking financial performance to the next level, I recognize the incredible promise in Wejo,” said Maxwell. “The company is on a trajectory that will not only see major transformation in the organization, but also has potential to change the world for the better—from smarter cars to safer roads and more sustainable cities. I am eager for the great opportunity ahead of me working with a growing, global company in a solid market position with no signs of slowing down.”

    For more on Wejo, please visit their website, www.wejo.com.

    About Wejo

    Wejo is the leader in connected vehicle data, revolutionizing the way we live, work and travel by transforming and interpreting historic and real-time vehicle data. The company enables smarter mobility by organizing trillions of data points from over 10.6 million vehicles and more than 42.3 billion journeys globally, across multiple brands, makes and models, and then standardizing and enhancing those streams of data on a vast scale. Wejo partners with ethical, like-minded companies and organizations to turn that data into insights that unlock value for consumers. With the most comprehensive and trusted data, information and intelligence, Wejo is creating a smarter, safer, more sustainable world for all. Founded in 2014, Wejo employs more than 150 people and has offices in Manchester in the UK and Detroit in the US. For more information, visit: www.wejo.com.

    Get the next $AQST alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AQST

    DatePrice TargetRatingAnalyst
    12/17/2024$17.00Overweight
    Cantor Fitzgerald
    5/10/2024$8.00Outperform
    Leerink Partners
    4/11/2024$10.00Overweight
    Piper Sandler
    3/28/2024$7.00Outperform
    Raymond James
    More analyst ratings

    $AQST
    SEC Filings

    See more
    • SEC Form DEFA14A filed by Aquestive Therapeutics Inc.

      DEFA14A - Aquestive Therapeutics, Inc. (0001398733) (Filer)

      4/25/25 4:33:10 PM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Aquestive Therapeutics Inc.

      DEF 14A - Aquestive Therapeutics, Inc. (0001398733) (Filer)

      4/25/25 4:31:57 PM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aquestive Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Aquestive Therapeutics, Inc. (0001398733) (Filer)

      4/1/25 8:26:39 AM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AQST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Cioffi Melina claimed ownership of 182,261 shares (SEC Form 3)

      3 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)

      5/7/25 9:10:34 AM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Science Officer Wargacki Stephen was granted 115,000 shares and covered exercise/tax liability with 32,862 shares, increasing direct ownership by 31% to 343,552 units (SEC Form 4)

      4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)

      3/11/25 5:49:10 PM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Jung Cassie was granted 80,000 shares and covered exercise/tax liability with 17,540 shares, increasing direct ownership by 27% to 295,526 units (SEC Form 4)

      4 - Aquestive Therapeutics, Inc. (0001398733) (Issuer)

      3/11/25 5:48:57 PM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AQST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Aquestive Therapeutics with a new price target

      Cantor Fitzgerald initiated coverage of Aquestive Therapeutics with a rating of Overweight and set a new price target of $17.00

      12/17/24 7:27:23 AM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leerink Partners initiated coverage on Aquestive Therapeutics with a new price target

      Leerink Partners initiated coverage of Aquestive Therapeutics with a rating of Outperform and set a new price target of $8.00

      5/10/24 7:29:48 AM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler initiated coverage on Aquestive Therapeutics with a new price target

      Piper Sandler initiated coverage of Aquestive Therapeutics with a rating of Overweight and set a new price target of $10.00

      4/11/24 7:28:12 AM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AQST
    Financials

    Live finance-specific insights

    See more
    • Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

      WARREN, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the first quarter ended March 31, 2025 and provide an update on recent developments in its business after market close on Monday, May 12, 2025. Management will host a conference call for investors at 8:00 a.m. ET on Tuesday, May 13, 2025. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the

      5/1/25 7:00:00 AM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      Initiated Anaphylm™ (epinephrine) Sublingual Film NDA filing process with FDAAnaphylm pre-commercial activities underway; launch expected in Q1 2026, if approved by the FDAInitial Anaphylm pediatric clinical trial results in subjects 7-17 years of age in line with expectationsAQST-108 (epinephrine) Topical Gel Phase 2a clinical trial on track to begin in Q2 2025Proforma cash and cash equivalents as of December 31, 2024 approximately $93.0 millionCompany to host investment community conference call on March 6, 2025 WARREN, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medi

      3/5/25 4:01:00 PM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET

      WARREN, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2024 and provide an update on recent developments in its business after market close on Wednesday, March 5, 2025. Management will host a conference call for investors at 8:00 a.m. ET on Thursday, March 6, 2025. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A

      2/20/25 7:00:00 AM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AQST
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Aquestive Therapeutics to Participate in Citizens Life Sciences Conference

      WARREN, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the upcoming Citizens Life Sciences Conference from May 7-8 in New York City. The Aquestive team will hold a fireside chat on May 8th at 10 am ET; management will also be hosting one-on-ones with investors that same day. A webcast of the fireside chat will be available under the "Events and Presentations" page of the Investors section of the Company's website.

      5/5/25 7:00:00 AM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8:00 a.m. ET

      WARREN, N.J., May 01, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the first quarter ended March 31, 2025 and provide an update on recent developments in its business after market close on Monday, May 12, 2025. Management will host a conference call for investors at 8:00 a.m. ET on Tuesday, May 13, 2025. To participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the

      5/1/25 7:00:00 AM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

      WARREN, N.J., April 09, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in the Piper Sandler Spring Biopharma Symposium in Boston. The Aquestive team will host investor meetings at the event on April 17. About Aquestive Therapeutics, Inc.Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing orally administere

      4/9/25 7:00:00 AM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AQST
    Leadership Updates

    Live Leadership Updates

    See more
    • Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024

      WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced its expected addition to the broad-market Russell 3000® and Russell 2000® Indexes at the conclusion of the 2024 Russell U.S. indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1, according to a preliminary list of additions posted Friday, May 24, 2024. "We are honored that Aquestive is joining the Russell 3000 Index, which represents the 3,000 largest U.S. public

      6/18/24 8:00:00 AM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive

      WARREN, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the appointment of Abigail Jenkins to the Company's Board of Directors, effective April 1, 2024. Ms. Jenkins has two decades of leadership in large and small biotech and pharmaceutical companies, with a focus on commercial launch and corporate strategy roles. "I am very pleased to welcome Abbey to the Aquestive Board of Directors. Her two decades of experience in the commercialization of pharmaceutical p

      4/1/24 8:00:00 AM ET
      $AQST
      $EBS
      $GMDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Aquestive Therapeutics Provides Business Update and Announces Chief Medical Officer Appointment

      Submitted NDA for Libervant™ (diazepam) Buccal Film for treatment of seizure clusters in patients between two and five years of ageAppointed Carl N. Kraus, M.D. as Chief Medical Officer WARREN, N.J., June 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) (the "Company" or "Aquestive"), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today provided an update on recent business developments and announced the appointment of Carl N. Kraus, M.D. as Chief Medical Officer of the Company. NDA Filing for Libervant for Pediatric PopulationAquestive submitted a N

      6/29/23 8:42:55 AM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AQST
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more

    $AQST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • FDA Approval for LIBERVANT issued to AQUESTIVE THERAPEUTICS INC

      Submission status for AQUESTIVE THERAPEUTICS INC's drug LIBERVANT (ORIG-1) with active ingredient DIAZEPAM has changed to 'Approval' on 04/26/2024. Application Category: NDA, Application Number: 218623, Application Classification: Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval

      4/29/24 7:48:13 AM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Aquestive Therapeutics Inc.

      SC 13G/A - Aquestive Therapeutics, Inc. (0001398733) (Subject)

      11/14/24 3:47:19 PM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aquestive Therapeutics Inc.

      SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)

      4/1/24 6:21:14 PM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Aquestive Therapeutics Inc.

      SC 13G - Aquestive Therapeutics, Inc. (0001398733) (Subject)

      2/14/24 3:24:42 PM ET
      $AQST
      Biotechnology: Pharmaceutical Preparations
      Health Care